Yuekang Pharmaceutical: Achieving RMB 2.45 billion in revenue in 2025, continuing to place R&D innovation at the core of strategic focus

LightningPacketLoss · 2026-03-21T08:59:52+00:00

Yuekan Pharmaceuticals' 2025 annual report shows that the operating revenue was 2.45 billion yuan, a decrease of 35.3% year-on-year, with a net loss of 262 million yuan. The company's losses further widened in the fourth quarter, as adjustments to sales strategies impacted performance. Despite these challenges, R&D investment accounted for 18.67% of revenue, reflecting a continued emphasis on future innovation.

LightningPacketLoss

2026-03-21 08:59:52

Abstract generation in progress

Recently, Yuekang Pharmaceutical announced its 2025 annual report, stating that the company’s operating revenue was 2.45 billion yuan, a decrease of 35.3% year-on-year; net profit attributable to shareholders was a loss of 262 million yuan, down 312.1% year-on-year; non-recurring net profit attributable to shareholders was a loss of 288 million yuan, down 360.0% year-on-year; net operating cash flow was 340 million yuan, a decrease of 22.4% year-on-year; EPS (fully diluted) was -0.5831 yuan.

In the fourth quarter, the company’s operating revenue was 687 million yuan, down 12.9% year-on-year; net profit attributable to shareholders shifted from a loss of 86.01 million yuan in the same period last year to a loss of 114 million yuan, further widening the loss; non-recurring net profit attributable to shareholders changed from a loss of 91.17 million yuan to a loss of 120 million yuan, further widening the loss; EPS was -0.2542 yuan.

In the management discussion and analysis for 2025, the company mentioned that its business operations faced significant changes. Specifically, at the end of 2024, the company adjusted the pricing and sales strategy for “Ginkgo Biloba Extract Injection,” which had a phased impact on revenue and profit. Additionally, the company continued to prioritize R&D innovation as a strategic core, with R&D expenses increasing year-on-year during the reporting period. R&D investment accounted for 18.67% of operating revenue, an increase of 7.51 percentage points compared to 2024, which to some extent affected net profit.

During the reporting period, the company continued to promote new drug R&D projects, especially in the fields of small nucleic acid drugs, mRNA vaccines, and peptide drugs, aiming to establish differentiated competitive advantages. Overall, despite declines in revenue and profit, the company maintained a high level of R&D investment to support future growth and innovation capabilities.

(Yuekang Pharmaceutical Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.